Akebia Therapeutics, Inc. (AKBA)
| Market Cap | 317.89M -44.6% |
| Revenue (ttm) | 232.40M +25.7% |
| Net Income | -20.51M |
| EPS | -0.08 |
| Shares Out | 268.26M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,423,206 |
| Open | 1.170 |
| Previous Close | 1.180 |
| Day's Range | 1.160 - 1.200 |
| 52-Week Range | 1.125 - 4.079 |
| Beta | 0.35 |
| Analysts | Strong Buy |
| Price Target | 4.67 (+294.09%) |
| Earnings Date | May 7, 2026 |
About AKBA
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia... [Read more]
Financial Performance
In 2025, Akebia Therapeutics's revenue was $236.20 million, an increase of 47.46% compared to the previous year's $160.18 million. Losses were -$5.35 million, -92.30% less than in 2024.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for AKBA stock is "Strong Buy." The 12-month stock price target is $4.67, which is an increase of 294.09% from the latest price.
News
Akebia Therapeutics Earnings Call Transcript: Q1 2026
Vafseo net product revenue grew 32% year-over-year in Q1 2026, offsetting declines in AURYXIA due to generic competition. Patient and prescriber adoption of Vafseo accelerated, with strong adherence rates and expanding observed dosing protocols, supporting future growth.
Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline Highlights
Q1 2026 Vafseo® (vadadustat) net product revenues grew to $15.8 million ; Q1 2026 total net product revenues of $52.0 million Number of patients treated with Vafseo increased 60% in Q1 2026 compared ...
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, gra...
Akebia Therapeutics Announces Vadadustat Post-hoc Win Statistics Analysis Demonstrating Statistically Significant Reduction in Mortality and Hospitalization Composite Endpoint Published in the Journal of American Society of Nephrology
CAMBRIDGE, Mass., May 04, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, tod...
Akebia Therapeutics to Report First Quarter 2026 Financial Results and Discuss Recent Business Highlights
Akebia to Host Conference Call on May 7 at 8:00 a.m. EDT CAMBRIDGE, Mass.
Akebia doses first participants in AKB-9090 trial
Akebia (AKBA) Therapeutics announced the first participants have been dosed in a Phase 1 clinical trial of AKB-9090, an internally developed hypoxia-inducible factor-prolyl hydroxylase inhibitor being...
Akebia Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of AKB-9090
CAMBRIDGE, Mass., April 13, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...
Akebia Therapeutics to Conduct Investor Meetings at the Raymond James 2026 Biotech Innovation Symposium
CAMBRIDGE, Mass., April 07, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...
Akebia Therapeutics Transcript: R&D Day 2026
The company is advancing a differentiated pipeline in kidney disease, with praliciguat, AKB-097, and AKB-9090 progressing through key clinical milestones. Vafseo is driving revenue growth, supporting R&D investments, and multiple catalysts are expected in the next year.
Akebia Therapeutics Appoints Biopharmaceutical Leader Philip Vickers, Ph.D. to its Board of Directors
CAMBRIDGE, Mass., April 01, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...
Akebia Therapeutics to Host Virtual R&D Day Highlighting Robust Kidney Disease Pipeline, on April 2, 2026
CAMBRIDGE, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...
Akebia Therapeutics Transcript: Leerink Global Healthcare Conference 2026
The company is focused on making Vafseo the standard of care for dialysis-related anemia, supported by strong clinical and economic data, and is expanding its kidney disease pipeline with praliciguat and AKB-097. Post-TDAPA, pricing will align with ESA benchmarks, targeting a $1B market.
Akebia Therapeutics to Present at the Leerink Partners 2026 Global Healthcare Conference
CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...
Akebia Therapeutics Earnings Call Transcript: Q4 2025
Net product revenues grew nearly 50% year-over-year to $236.2 million in 2025, driven by Vafseo's launch and Auryxia sales, while net loss narrowed significantly. Vafseo adoption is expanding, with improved adherence and broader access, and the pipeline is advancing with multiple clinical milestones ahead.
Akebia Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial and Pipeline Highlights
Q4 2025 net product revenues of $54.3 million ; 2025 full-year net product revenues of $227.3 million , representing a 49% increase over 2024 full-year net product revenues Expect significant Vafseo®...
Akebia price target lowered to $4 from $5 at BTIG
BTIG lowered the firm’s price target on Akebia (AKBA) to $4 from $5 and keeps a Buy rating on the shares. The firm is citing a new US Renal Care…
Akebia Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Discuss Recent Business Highlights
CAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the fourth quarter and full year ended December...
Akebia Therapeutics Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026
The company is advancing its kidney disease portfolio, with VAFSEO gaining traction in dialysis anemia and new dosing strategies reducing discontinuation rates. Key clinical readouts for VAFSEO and pipeline assets like praliciguat and AKB-097 are expected over the next 12–24 months.
Akebia price target lowered to $4 from $6 at Piper Sandler
Piper Sandler analyst Allison Bratzel lowered the firm’s price target on Akebia (AKBA) to $4 from $6 and keeps an Overweight rating on the shares. Following a number of Q4/FY25…
Akebia Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
CAMBRIDGE, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, ...
Akebia announces corporate updates, 2026 pipeline outlook
Akebia (AKBA) Therapeutics announced key corporate updates associated with its Vafseo commercial business and provided an outlook on upcoming milestones, including for its next anticipated growth driv...
Akebia Therapeutics Announces Corporate Updates and 2026 Pipeline Outlook
Positioned to increase depth of Vafseo prescribing entering 2026 with access to approximately 275,000 patients First patient dosed in Praliciguat Phase 2 clinical trial studying focal segmental glomer...
Akebia announces first patient dosed in Phase 2 trial of praliciguat
Akebia (AKBA) Therapeutics announced that the first patient has been dosed in a Phase 2 clinical trial of praliciguat, an oral, once-daily soluble guanylate cyclase, sGC, stimulator being evaluated fo...
Akebia Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Praliciguat for the Treatment of Focal Segmental Glomerulosclerosis (FSGS)
CAMBRIDGE, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, ...
Akebia Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference
The company is expanding its kidney disease portfolio with new pipeline assets and a successful Vafseo launch, despite operational and pricing challenges. Clinical data supports Vafseo's benefits, and new acquisitions strengthen the rare disease pipeline.